Compare ICUI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICUI | NUVB |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.9B |
| IPO Year | 1992 | N/A |
| Metric | ICUI | NUVB |
|---|---|---|
| Price | $153.50 | $5.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $179.50 | $10.44 |
| AVG Volume (30 Days) | 217.4K | ★ 6.3M |
| Earning Date | 02-26-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,320,363,000.00 | $26,748,000.00 |
| Revenue This Year | N/A | $616.63 |
| Revenue Next Year | N/A | $202.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1137.19 |
| 52 Week Low | $107.00 | $1.54 |
| 52 Week High | $175.51 | $9.75 |
| Indicator | ICUI | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 58.58 | 29.46 |
| Support Level | $146.33 | $6.07 |
| Resistance Level | $157.91 | $6.63 |
| Average True Range (ATR) | 5.21 | 0.53 |
| MACD | 0.41 | -0.39 |
| Stochastic Oscillator | 76.51 | 11.03 |
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.